Home > Drugs A-Z > Belladonna Alkaloids with Phenobartbital

Belladonna Alkaloids with Phenobartbital (Legacy Pharmaceutical Packaging)

Available Formats

Dosage Form Package Information Links
TABLET 60 TABLET in 1 BOTTLE (68645-230-59) Label Information

Complete Belladonna Alkaloids with Phenobartbital Information

  • BOXED WARNING(What is this?)

    INDICATIONS AND USAGE:

    Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the following indications as “possibly” effective:

    For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.

    May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.


  • DESCRIPTION:

    Each Tablet contains:

                Atropine Sulfate, USP..........................0.0194 mg
                Hyoscyamine Sulfate, USP.................0.1037 mg
                Scopolamine Hydrobromide, USP.....0.0065 mg
                Phenobarbital, USP..................................16.2 mg

    Inactive ingredients: Anhydrous Lactose, Calcium Stearate, Colloidal Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose.


  • CLINICAL PHARMACOLOGY:

    This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation.


  • CONTRAINDICATIONS:

    Glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic magacolon; myasthenia gravis; hiatal hernia associated with reflux esophagitis.

    Belladonna alkaloids with phenobarbital tablets are contraindicated in patients with known hypersensitivity to any of the ingredients. Phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.


  • WARNINGS:

    In the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and heatstroke due to decreased sweating).

    Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.

    Belladonna alkaloids with phenobarbital tablets may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.

    Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.

    Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs.

    Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in patients with hepatic dysfunction.


  • PRECAUTIONS:

    Use with caution in patients with: autonomic neuropathy, hepatic or renal disease, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia, and hypertension.

    Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management of gastric ulcer.

    Theoretically, with overdosage, a curare-like action may occur.

    Carcinogenesis, mutagenesis.

    Long-term studies in animals have not been performed to evaluate carcinogenic potential.

    Pregnancy Category C.

    Animal reproduction studies have not been conducted with belladonna alkaloids with phenobarbital tablets. It is not known whether belladonna alkaloids with phenobarbital tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Belladonna alkaloids with phenobarbital tablets should be given to a pregnant woman only if clearly needed.

    Nursing mothers.

    It is not know whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when belladonna alkaloids with phenobarbital tablets are administered to a nursing mother.


  • ADVERSE REACTIONS:

    Adverse reactions may include xerostomia, urinary hesitancy and retention; blurred vision; tachycardia; palpitation; mydriasis; cycloplegia; increased ocular tension; loss of taste sense; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; musculoskeletal pain; severe allergic reaction or drug idiosyncrasies, including anaphylaxis, urticaria and other dermal manifestations; and decreased sweating. Elderly patients may react with symptoms of excitement, agitation, drowsiness, and other untoward manifestations to even small doses of the drug. Phenobarbital may produce excitement in some patients, rather than a sedative effect. In patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.


  • DOSAGE AND ADMINISTRATION:

    The dosage of belladonna alkaloids with phenobarbital tablets should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse effects.

    Adults: One or two tablets three or four times a day according to condition and severity of symptoms.


  • OVERDOSAGE:

    The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot and dry skin, dizziness, dryness of the mouth, difficulty in swallowing, CNS stimulation. Treatment should consist of gastric lavage, emetics and activated charcoal. If indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride, should be added.


  • HOW SUPPLIED:

    Belladonna Alkaloids with Phenobarbital Tablets are supplied as; White, round, scored, compressed tablets imprinted â€œWest-ward 140”.

    Bottles of 60 tablets.

    Manufactured by:
    West-Ward Pharmaceutical Corp.
    Eatontown, NJ 07724

    Packaged by:
    Legacy Pharmaceutical Packaging
    Earth City, MO 63045

    Distributed by:
    Wal-Mart
    Bentonville, AR 72716

    Store at 20 – 25° C (68- 77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.

    Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.


  • PRINCIPAL DISPLAY PANEL

    NDC 68645-230-59
    Belladonna Alkaloids with Phenobarbital Tablets
    Rx Only
    60 Tablets

    NDC 68645-230-59 Belladonna Alkaloids with Phenobarbital Tablets Rx Only 60 Tablets

    60 Tablets

    Rx Only

    USUAL ADULT DOSAGE: See accompanying product literature for complete information.

    Store at 20 – 25° C (68- 77°F) [See USP Controlled Room Temperature].

    Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

    Each Tablet contains:

    Hyoscyamine Sulfate, USP...............0.1037 mg
    Atropine Sulfate, USP.......................0.0194 mg
    Scopolamine HBr, USP....................0.0065 mg
    Phenobarbital, USP...............................16.2 mg


  • INGREDIENTS AND APPEARANCE
    BELLADONNA ALKALOIDS WITH PHENOBARTBITAL 
    belladonna alkaloids with phenobartbital tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68645-230(NDC:0143-1140)
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    ATROPINE SULFATE (UNII: 03J5ZE7KA5) (ATROPINE - UNII:7C0697DR9I) ATROPINE SULFATE 0.0194 mg
    HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X) HYOSCYAMINE SULFATE 0.1037 mg
    SCOPOLAMINE HYDROBROMIDE (UNII: 451IFR0GXB) (SCOPOLAMINE - UNII:DL48G20X8X) SCOPOLAMINE HYDROBROMIDE 0.0065 mg
    PHENOBARBITAL (UNII: YQE403BP4D) (PHENOBARBITAL - UNII:YQE403BP4D) PHENOBARBITAL 16.2 mg
    Inactive Ingredients
    Ingredient Name Strength
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    Product Characteristics
    Color WHITE Score 2 pieces
    Shape ROUND Size 8mm
    Flavor Imprint Code West;ward;140
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:68645-230-59 60 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    UNAPPROVED DRUG OTHER 12/01/2000
    Labeler - Legacy Pharmaceutical Packaging (143213275)
    Establishment
    Name Address ID/FEI Business Operations
    Legacy Pharmaceutical Packaging 143213275 RELABEL, REPACK